Literature DB >> 10436787

Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors.

V W van Hinsbergh1, A Collen, P Koolwijk.   

Abstract

Angiogenesis is the formation of new blood vessels from preexisting ones. Many solid tumors depend on an extensive newly formed vascular network to become nourished and to expand. Tumor cells induce the formation of an extensive but aberrant vascular network by the secretion of angiogenic factors. A proper context is needed for the endothelial cells to respond. To create this proper context, the tumor often uses the body's own repair system to accelerate angiogenesis and the subsequent tumor expansion. The angiogenic response is governed by the interaction of angiogenic growth factors and cytokines with specific receptors on the endothelium, as well as by the interaction of these cells with their surrounding matrix, which is regulated by matrix-degrading proteases and adhesion molecules such as integrins. A number of agents have been discovered and developed that aim to inhibit angiogenesis and to convert the tumor to a dormant state. They have proven to be effective in animal studies. At present their efficacy in man is under evaluation.

Entities:  

Mesh:

Year:  1999        PMID: 10436787

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

1.  AngioDB: database of angiogenesis and angiogenesis-related molecules.

Authors:  Tae-Kwon Sohn; Eun-Joung Moon; Seok-Ki Lee; Hwan-Gue Cho; Kyu-Won Kim
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

3.  Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.

Authors:  Lijun Wang; Jiyun Shi; Young-Seung Kim; Shizhen Zhai; Bing Jia; Huiyun Zhao; Zhaofei Liu; Fan Wang; Xiaoyuan Chen; Shuang Liu
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

4.  A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.

Authors:  Laura Q M Chow; Daniel L Gustafson; Cindy L O'Bryant; Lia Gore; Michele Basche; Scott N Holden; Mark C Morrow; Stacy Grolnic; Brian R Creese; Kaye L Roberts; Kat Davis; Russell Addison; S Gail Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  2008-03-05       Impact factor: 3.333

5.  URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway.

Authors:  Sizhong Xing; Bing Zhang; Ruixi Hua; William Chi-shing Tai; Zhirong Zeng; Binhui Xie; Chenghui Huang; Jisu Xue; Shiqiu Xiong; Jianyong Yang; Side Liu; Heping Li
Journal:  BMC Cancer       Date:  2015-05-07       Impact factor: 4.430

Review 6.  Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.

Authors:  Guido Giordano; Antonio Febbraro; Michele Venditti; Serena Campidoglio; Nunzio Olivieri; Katia Raieta; Pietro Parcesepe; Giusy Carmen Imbriani; Andrea Remo; Massimo Pancione
Journal:  Gastroenterol Res Pract       Date:  2014-07-21       Impact factor: 2.260

Review 7.  The Role of CC-Chemokines in the Regulation of Angiogenesis.

Authors:  Anisyah Ridiandries; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2016-11-08       Impact factor: 5.923

8.  lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway.

Authors:  Qi Zhang; Tianfu Li; Zhecun Wang; Xiaying Kuang; Nan Shao; Ying Lin
Journal:  J Cell Mol Med       Date:  2020-06-17       Impact factor: 5.310

9.  PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.

Authors:  Lujin Wu; Wei Wang; Meiyan Dai; Huihui Li; Chen Chen; Daowen Wang
Journal:  BMC Cancer       Date:  2019-12-02       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.